These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28574805)

  • 1. The Development of FVIII Inhibitors in Relation to IL10 Gene Polymorphism in Hemophilia A Egyptian Pediatric Patients.
    Sadek H; Youssry I; Ibrahim NSE; Abou-Elalla AA; Atef G; Mousa SM
    Fetal Pediatr Pathol; 2017 Jun; 36(3):184-189. PubMed ID: 28574805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?
    Sherief LM; Gaber OA; Youssef HM; Sherbiny HS; Mokhtar WA; Ali AAA; Kamal NM; Abdel Maksoud YH
    Ital J Pediatr; 2020 Sep; 46(1):129. PubMed ID: 32928254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?
    Franchini M; Lippi G
    Thromb Res; 2016 Dec; 148():96-100. PubMed ID: 27816852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
    Sharathkumar A; Lillicrap D; Blanchette VS; Kern M; Leggo J; Stain AM; Brooker L; Carcao MD
    J Thromb Haemost; 2003 Jun; 1(6):1228-36. PubMed ID: 12871324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A.
    Pergantou H; Varela I; Moraloglou O; Economou M; Spanou K; Kapsimali Z; Constantinidou N; Platokouki H
    Haemophilia; 2013 Sep; 19(5):706-10. PubMed ID: 23607306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Leebeek FWG; Escuriola-Ettingshausen C; Hermans C; Keenan R; Astermark J; Male C; Peerlinck K; le Cessie S; van der Bom JG; Fijnvandraat K
    J Thromb Haemost; 2017 Jul; 15(7):1422-1429. PubMed ID: 28440011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.
    Kreuz W; Becker S; Lenz E; Martinez-Saguer I; Escuriola-Ettingshausen C; Funk M; Ehrenforth S; Auerswald G; Kornhuber B
    Semin Thromb Hemost; 1995; 21(4):382-9. PubMed ID: 8747701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A close insight to factor VIII inhibitor in the congenital hemophilia A.
    Tabriznia-Tabrizi S; Gholampour M; Mansouritorghabeh H
    Expert Rev Hematol; 2016 Sep; 9(9):903-13. PubMed ID: 27367203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune response to FVIII in hemophilia A: an overview of risk factors.
    Ghosh K; Shetty S
    Clin Rev Allergy Immunol; 2009 Oct; 37(2):58-66. PubMed ID: 19148784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A.
    Chaves D; Belisário A; Castro G; Santoro M; Rodrigues C
    Int J Immunogenet; 2010 Apr; 37(2):79-82. PubMed ID: 20082647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
    Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
    Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.
    Klintman J; Hillarp A; Berntorp E; Astermark J
    Br J Haematol; 2013 Nov; 163(3):385-92. PubMed ID: 24032553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A.
    Bafunno V; Santacroce R; Chetta M; D'Andrea G; Pisanelli D; Sessa F; Trotta T; Tagariello G; Peyvandi F; Margaglione M
    Haemophilia; 2010 May; 16(3):469-73. PubMed ID: 20015215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Screening and analysis of coagulation factor VIII inhibitor in patients with hemophilia A].
    Zhang AL; Yang LH; Liu XE; Zhao H; Zhang JH; Dong CX; Qi XL; Qin XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):968-70. PubMed ID: 21867625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of inhibitor against hemophilia and prevention and management strategies forpatients with hemophilia].
    Wu RH; Wei QQ
    Zhonghua Er Ke Za Zhi; 2013 Aug; 51(8):631-4. PubMed ID: 24225299
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.
    Bachelet D; Albert T; Mbogning C; Hässler S; Zhang Y; Schultze-Strasser S; Repessé Y; Rayes J; Pavlova A; Pezeshkpoor B; Liphardt K; Davidson JE; Hincelin-Méry A; Dönnes P; Lacroix-Desmazes S; Königs C; Oldenburg J; Broët P;
    PLoS One; 2019; 14(6):e0218258. PubMed ID: 31194850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.